Disease-specific Analyses of Unrelated Cord Blood Transplantation Compared with Unrelated Bone Marrow Transplantation in Adult Patients with Acute Leukemia
Overview
Authors
Affiliations
We made a disease-specific comparison of unrelated cord blood (CB) recipients and human leukocyte antigen allele-matched unrelated bone marrow (BM) recipients among 484 patients with acute myeloid leukemia (AML; 173 CB and 311 BM) and 336 patients with acute lymphoblastic leukemia (ALL; 114 CB and 222 BM) who received myeloablative transplantations. In multivariate analyses, among AML cases, lower overall survival (hazard ratio [HR]=1.5; 95% confidence interval [CI], 1.0-2.0, P= .028) and leukemia-free survival (HR=1.5; 95% CI, 1.1-2.0, P= .012) were observed in CB recipients. The relapse rate did not differ between the 2 groups of AML (HR=1.2; 95% CI, 0.8-1.9, P= .38); however, the treatment-related mortality rate showed higher trend in CB recipients (HR=1.5; 95% CI, 1.0-2.3, P= .085). In ALL, there was no significant difference between the groups for relapse (HR=1.4, 95% CI, 0.8-2.4, P= .19) and treatment-related mortality (HR=1.0; 95% CI, 0.6-1.7, P= .98), which contributed to similar overall survival (HR=1.1; 95% CI, 0.7-1.6, P= .78) and leukemia-free survival (HR=1.2; 95% CI, 0.9-1.8, P= .28). Matched or mismatched single-unit CB is a favorable alternative stem cell source for patients without a human leukocyte antigen-matched related or unrelated donor. For patients with AML, decreasing mortality, especially in the early phase of transplantation, is required to improve the outcome for CB recipients.
Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.
Sugita J, Morita K, Konuma T, Yanada M Ann Hematol. 2024; 103(12):4851-4868.
PMID: 39153145 DOI: 10.1007/s00277-024-05944-0.
Nukui J, Tachibana T, Miyazaki T, Tanaka M, Matsumoto K, Ishii Y Int J Hematol. 2023; 119(1):62-70.
PMID: 38082200 DOI: 10.1007/s12185-023-03688-7.
Chimeric antigen receptor engineered natural killer cells for cancer therapy.
Zhang Y, Zhou W, Yang J, Yang J, Wang W Exp Hematol Oncol. 2023; 12(1):70.
PMID: 37563648 PMC: 10413722. DOI: 10.1186/s40164-023-00431-0.
CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies.
Faeq M, Al-Haideri M, Merza Mohammad T, Gharebakhshi F, Marofi F, Tahmasebi S Med Oncol. 2023; 40(5):155.
PMID: 37083979 PMC: 10119530. DOI: 10.1007/s12032-023-02019-4.
Chen D, Wang P, Hour A, Lin W, Hsu F, Wang W Front Immunol. 2023; 14:1093514.
PMID: 36911734 PMC: 9995383. DOI: 10.3389/fimmu.2023.1093514.